Raseglurant, aslo known as ADX-10059, is a negative allosteric modulator of the mGlu5 receptor and analogue of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety. It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use. References: Marin JC, Goadsby PJ. Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine? Expert Opin Investig Drugs. 2010 Apr;19(4):555-61. doi: 10.1517/13543781003691832. Review. PubMed PMID: 20218930.

纯度：≥98%

CAS：757950-09-7